{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:16:34Z","timestamp":1790662594944,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1053\/j.ackd.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:58:00Z","timestamp":1567195080000},"page":"272-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease"],"prefix":"10.1053","volume":"26","author":[{"given":"Pablo E.","family":"Pergola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2830-5469","authenticated-orcid":false,"given":"Tomas","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib1","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1053\/j.ackd.2019.05.002_bib2","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1053\/j.ackd.2019.05.002_bib3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ackd.2019.05.002_bib5","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1185\/030079904X2763","article-title":"The prevalence of anemia in patients with chronic kidney disease","volume":"20","author":"McClellan","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1053\/j.ackd.2019.05.002_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ackd.2019.05.002_bib7","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","article-title":"Hepcidin and iron homeostasis","volume":"1823","author":"Ganz","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"issue":"6692","key":"10.1053\/j.ackd.2019.05.002_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.299.6692.157","article-title":"Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously","volume":"299","author":"Macdougall","year":"1989","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.05.002_bib10","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: beyond serum ferritin and transferrin saturation","volume":"1","author":"Wish","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.05.002_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2215\/CJN.01670408","article-title":"Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004","volume":"4","author":"Fishbane","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.05.002_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40261-016-0378-y","article-title":"The safety of erythropoiesis-stimulating agents for the treatment of anemia resulting from chronic kidney disease","volume":"36","author":"Robles","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"12","key":"10.1053\/j.ackd.2019.05.002_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD","volume":"62","author":"Kliger","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.05.002_bib15","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ckj\/sfx043","article-title":"Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions","volume":"10","author":"Macdougall","year":"2017","journal-title":"Clin Kidney J"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.05.002_bib16","first-page":"S21","article-title":"Markers of iron status in chronic kidney disease","volume":"21","author":"Gaweda","year":"2017","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.05.002_bib17","doi-asserted-by":"crossref","first-page":"e0191541","DOI":"10.1371\/journal.pone.0191541","article-title":"Iron deficiency across chronic kidney disease stages: is there a reverse gender pattern?","volume":"13","author":"Aoun","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis","volume":"52","author":"Rozen-Zvi","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.semnephrol.2016.05.002","article-title":"Disorders of iron metabolism and anemia in chronic kidney disease","volume":"36","author":"Panwar","year":"2016","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2019.05.002_bib21","doi-asserted-by":"crossref","first-page":"846824","DOI":"10.1100\/2012\/846824","article-title":"Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview","volume":"2012","author":"Santiago","year":"2012","journal-title":"Scientific World Journal"},{"issue":"7","key":"10.1053\/j.ackd.2019.05.002_bib22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4155\/cli.14.54","article-title":"Oral iron therapies in development for\u00a0iron deficiency in chronic kidney disease","volume":"4","author":"Mudge","year":"2014","journal-title":"Clin Invest"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1185\/03007995.2012.761599","article-title":"Tolerability of different oral iron supplements: a systematic review","volume":"29","author":"Cancelo-Hidalgo","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1053\/j.ackd.2019.05.002_bib24","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib25","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi","year":"2011","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2019.05.002_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2369-14-64","article-title":"Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial","volume":"14","author":"Nagaraju","year":"2013","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ndt\/gfs528","article-title":"Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study","volume":"28","author":"Charytan","year":"2013","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"10.1053\/j.ackd.2019.05.002_bib29","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ndt\/gfv293","article-title":"A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia","volume":"31","author":"Kalra","year":"2016","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000113529","article-title":"Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia","volume":"26","author":"Li","year":"2008","journal-title":"Blood Purif"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/089686080802800210","article-title":"Intravenous iron sucrose in peritoneal dialysis patients with renal anemia","volume":"28","author":"Li","year":"2008","journal-title":"Perit Dial Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin","volume":"19","author":"Kapoian","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2215\/CJN.02840608","article-title":"Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients","volume":"4","author":"Provenzano","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2019.05.002_bib37","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","article-title":"A randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients","volume":"30","author":"Bhandari","year":"2015","journal-title":"Nephrol Dial Transpl"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.05.002_bib38","first-page":"S78","article-title":"Iron deficiency anemia in chronic kidney disease: uncertainties and cautions","volume":"21","author":"Agarwal","year":"2017","journal-title":"Hemodial Int"},{"issue":"9","key":"10.1053\/j.ackd.2019.05.002_bib39","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/ndt\/gfw264","article-title":"Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial","volume":"32","author":"Roger","year":"2017","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"40","key":"10.1053\/j.ackd.2019.05.002_bib42","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1039\/b910970f","article-title":"Iron(III) citrate speciation in aqueous solution","author":"Silva","year":"2009","journal-title":"Dalton Trans"},{"key":"10.1053\/j.ackd.2019.05.002_bib43","unstructured":"Kwok DWK, Stoynov NM, inventors; Panion & BF Biotech, Inc, assignee. Ferric organic compounds, uses thereof and methods of making same. US patent 9,913,821. March 13, 2018."},{"issue":"6","key":"10.1053\/j.ackd.2019.05.002_bib44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1681\/ASN.V1061274","article-title":"New phosphate binding agents: ferric compounds","volume":"10","author":"Hsu","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"31","key":"10.1053\/j.ackd.2019.05.002_bib45","doi-asserted-by":"crossref","first-page":"12727","DOI":"10.1074\/jbc.R117.781823","article-title":"Iron homeostasis: an anthropocentric perspective","volume":"292","author":"Coffey","year":"2017","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib46","doi-asserted-by":"crossref","first-page":"a011668","DOI":"10.1101\/cshperspect.a011668","article-title":"Iron metabolism: interactions with normal and disordered erythropoiesis","volume":"2","author":"Ganz","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","article-title":"Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial","volume":"61","author":"Dwyer","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2019.05.002_bib49","series-title":"AURYXIA\u00ae [Prescribing information]","year":"2017"},{"issue":"10","key":"10.1053\/j.ackd.2019.05.002_bib50","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.05.002_bib51","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1-2","key":"10.1053\/j.ackd.2019.05.002_bib52","doi-asserted-by":"crossref","first-page":"c25","DOI":"10.1159\/000341922","article-title":"The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients","volume":"121","author":"Sinsakul","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.jrn.2014.03.006","article-title":"Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis","volume":"24","author":"Yokoyama","year":"2014","journal-title":"J Ren Nutr"},{"issue":"1-2","key":"10.1053\/j.ackd.2019.05.002_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000366482","article-title":"JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis","volume":"128","author":"Yokoyama","year":"2014","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"10.1053\/j.ackd.2019.05.002_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40620-014-0108-6","article-title":"Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Lee","year":"2015","journal-title":"J Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib56","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.05.002_bib57","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.05.002_bib58","first-page":"S104","article-title":"Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis","volume":"21","author":"Fishbane","year":"2017","journal-title":"Hemodial Int"},{"issue":"6","key":"10.1053\/j.ackd.2019.05.002_bib59","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.1002\/ajh.25088","article-title":"Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia","volume":"93","author":"Pergola","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.amjcard.2018.04.062","article-title":"Usefulness of oral ferric citrate in patients with iron-deficiency anemia and chronic kidney disease with or without heart failure","volume":"122","author":"McCullough","year":"2018","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib61","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CN108924","article-title":"The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis","volume":"87","author":"Umanath","year":"2017","journal-title":"Clin Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.05.002_bib62","doi-asserted-by":"crossref","first-page":"i637","DOI":"10.1093\/ndt\/gfy146.LB05","article-title":"LB05 randomized trial of the effects of ferric citrate in patients with advanced chronic kidney disease","volume":"33","author":"Block","year":"2018","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.23628","article-title":"Diagnosis and treatment of cancer-related anemia","volume":"89","author":"Gilreath","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.ackd.2019.05.002_bib65","doi-asserted-by":"crossref","first-page":"e0188712","DOI":"10.1371\/journal.pone.0188712","article-title":"Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease","volume":"12","author":"Chertow","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.ackd.2019.05.002_bib66","first-page":"CD007857","article-title":"Parenteral versus oral iron therapy for adults and children with chronic kidney disease","volume":"1","author":"Albaramki","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.2042-7158.1987.tb06249.x","article-title":"Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine","volume":"39","author":"Barrand","year":"1987","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib68","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1476-5381.1991.tb12240.x","article-title":"Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat","volume":"102","author":"Barrand","year":"1991","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib69","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2257.1989.tb00222.x","article-title":"Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects","volume":"11","author":"Kelsey","year":"1989","journal-title":"Clin Lab Haematol"},{"issue":"2","key":"10.1053\/j.ackd.2019.05.002_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2710.1991.tb00292.x","article-title":"Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test","volume":"16","author":"Kelsey","year":"1991","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.2042-7158.1990.tb05407.x","article-title":"Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate","volume":"42","author":"Singh","year":"1990","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1053\/j.ackd.2019.05.002_bib72","unstructured":"Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru\u00ae for the treatment of iron deficiency with the US Food and Drug Administration (FDA) [news release]. Shield Therapeutics plc; October 1, 2018. https:\/\/www.shieldtherapeutics.com\/rns_news\/submission-of-an-nda-for-feraccru-with-the-fda\/. Accessed June 19, 2019."},{"issue":"9","key":"10.1053\/j.ackd.2019.05.002_bib73","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1998.00380.x","article-title":"Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron","volume":"12","author":"Harvey","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.ackd.2019.05.002_bib74","first-page":"70","article-title":"AEGIS-CKD Study Group. Efficacy and safety of oral ferric maltol (FM) in treating iron-deficiency anemia (IDA) in patients\u00a0with CKD: Randomized controlled trial [FR-OR120]","volume":"29","author":"Kopyt","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"10.1053\/j.ackd.2019.05.002_bib75","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood.V128.22.3618.3618","article-title":"Sucrosomial technology is able to promote ferric iron absorption: pre-clinical and clinical evidences","volume":"128","author":"Brilli","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.ackd.2019.05.002_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/ph11040097","article-title":"Sucrosomial((R)) iron: a new generation iron for improving oral supplementation","volume":"11","author":"Gomez-Ramirez","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Jan 1","key":"10.1053\/j.ackd.2019.05.002_bib77","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ejps.2017.10.021","article-title":"Sucrosomial(R) iron absorption studied by in\u00a0vitro and ex-vivo models","volume":"111","author":"Fabiano","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1053\/j.ackd.2019.05.002_bib78","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3390\/ijms19092722","article-title":"Ex\u00a0vivo and in\u00a0vivo study of sucrosomial((R)) iron intestinal absorption and bioavailability","volume":"19","author":"Fabiano","year":"2018","journal-title":"Int J\u00a0Mol Sci"},{"issue":"23","key":"10.1053\/j.ackd.2019.05.002_bib79","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood.V126.23.4561.4561","article-title":"Sucrosomial Iron\u00ae: a new highly bioavailable oral iron supplement","volume":"126","author":"Tarantino","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.ackd.2019.05.002_bib80","first-page":"E286","article-title":"Comparison of the therapeutical potential of oral Sucrosomial\u00ae iron and parenteral iron dextran supplementations in neonatal iron deficiency anemia in pigs","volume":"92","author":"Starzy\u0144ski","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.ackd.2019.05.002_bib81","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/nu10101349","article-title":"Sucrosomial((R)) iron supplementation in mice: effects on blood parameters, hepcidin, and inflammation","volume":"10","author":"Asperti","year":"2018","journal-title":"Nutrients"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib82","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/nu10030330","article-title":"Sucrosomial iron supplementation in anemic patients with celiac disease not tolerating oral ferrous sulfate: a prospective study","volume":"10","author":"Elli","year":"2018","journal-title":"Nutrients"},{"issue":"15","key":"10.1053\/j.ackd.2019.05.002_bib83","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1080\/14767058.2016.1224841","article-title":"Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial","volume":"30","author":"Parisi","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"9","key":"10.1053\/j.ackd.2019.05.002_bib84","first-page":"2779","article-title":"Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study","volume":"25","author":"Mafodda","year":"2017","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1053\/j.ackd.2019.05.002_bib85","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11739-018-1993-9","article-title":"Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia","volume":"14","author":"Abbati","year":"2019","journal-title":"Intern Emerg Med"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:01:18Z","timestamp":1761548478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519301144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1548559519301144"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.05.002","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}